why choose us

First received: January 8, 2023

Clinical Trial: Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity

Study Status: Completed

Recruit Status: Completed

Condition: Retina Disease
Retinopathy of Prematurity
Ranibizumab

Study Type: Interventional


Official Title: Intravitreal Ranibizumab Injection In Aggressive Retinopathy Of Prematurity Compared With Type 1 Prethreshold Retinopathy Of Prematurity

Brief Summary: Despite advances in the neonatal intensive care units, retinopathy of prematurity (ROP) has become a common reason for blindness and visual disabilities in premature infants so that it accounts for about 5% and 30% of such complications in developed and developing countries. The pathophysiology of ROP is multifactorial. Supplemental oxygen demand and lower gestational age (GA) and birth weight (BW) are among the major risk factors for the occurrence and progression of ROP.Anti-vascular endothelial growth factor…

Read more